BACKGROUND: Pancreatic adenocarcinoma (PAC) has low overall survival (OS) rates and high recurrence rates following surgical resection. The role for preoperative radiation therapy (prRT) for PAC versus postoperative RT (poRT) remains uncertain. The authors used the National Cancer Data Base (NCDB) to report prRT outcomes for the largest multi-institutional patient cohort to date. METHODS: NCDB data were obtained for all patients who underwent resection and external beam radiation (RT) for PAC from 1998 to 2002. Patients with metastatic (M1) disease, intraoperative RT, RT both before and after surgery, missing OS, or missing RT variables were excluded. Univariate (UV) and multivariate (MV) analysis were run using treatment characteristics, tumor characteristics, and patient demographics. The difference in patients' known characteristics was described by a chi-square test or analysis of variance. RESULTS: A total of 5414 patients were identified. Of these, 277 received prRT and 5137 received poRT. Overall, 92.9% received chemotherapy and 7.1% received RT alone; 56% (2990 of 5307) of patients had stage III disease, according to American Joint Commission on Cancer (AJCC) staging manual, 5th edition. Median tumor size was 3 cm (range: 0-9.9 cm); 82% (199 of 244) of patients with prRT had negative surgical margins; 72% (3383 of 4699) of patients with poRT had negative margins. Forty-one percent (71 of 173) of patients with prRT were lymph node (LN)-positive; 65% (3159 of 4833) of patients with poRT were LN-positive. Median OS for patients with prRT was 18 months (95% CI = 18-19 months) and for patients with poRT, 19 months (95% CI = 17-22 months). CONCLUSIONS: Receipt of prRT was associated with lower stage, higher rates of negative margins, and lower rates of lymph node positivity at resection. However, there was no significant difference in median OS versus that of the poRT group.
BACKGROUND:Pancreatic adenocarcinoma (PAC) has low overall survival (OS) rates and high recurrence rates following surgical resection. The role for preoperative radiation therapy (prRT) for PAC versus postoperative RT (poRT) remains uncertain. The authors used the National Cancer Data Base (NCDB) to report prRT outcomes for the largest multi-institutional patient cohort to date. METHODS: NCDB data were obtained for all patients who underwent resection and external beam radiation (RT) for PAC from 1998 to 2002. Patients with metastatic (M1) disease, intraoperative RT, RT both before and after surgery, missing OS, or missing RT variables were excluded. Univariate (UV) and multivariate (MV) analysis were run using treatment characteristics, tumor characteristics, and patient demographics. The difference in patients' known characteristics was described by a chi-square test or analysis of variance. RESULTS: A total of 5414 patients were identified. Of these, 277 received prRT and 5137 received poRT. Overall, 92.9% received chemotherapy and 7.1% received RT alone; 56% (2990 of 5307) of patients had stage III disease, according to American Joint Commission on Cancer (AJCC) staging manual, 5th edition. Median tumor size was 3 cm (range: 0-9.9 cm); 82% (199 of 244) of patients with prRT had negative surgical margins; 72% (3383 of 4699) of patients with poRT had negative margins. Forty-one percent (71 of 173) of patients with prRT were lymph node (LN)-positive; 65% (3159 of 4833) of patients with poRT were LN-positive. Median OS for patients with prRT was 18 months (95% CI = 18-19 months) and for patients with poRT, 19 months (95% CI = 17-22 months). CONCLUSIONS: Receipt of prRT was associated with lower stage, higher rates of negative margins, and lower rates of lymph node positivity at resection. However, there was no significant difference in median OS versus that of the poRT group.
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Mark S Talamonti; William Small; Mary F Mulcahy; Jeffrey D Wayne; Vikram Attaluri; Lisa M Colletti; Mark M Zalupski; John P Hoffman; Gary M Freedman; Timothy J Kinsella; Philip A Philip; Cornelius J McGinn Journal: Ann Surg Oncol Date: 2006-01-19 Impact factor: 5.344
Authors: F R Spitz; J L Abbruzzese; J E Lee; P W Pisters; A M Lowy; C J Fenoglio; K R Cleary; N A Janjan; M S Goswitz; T A Rich; D B Evans Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: J F Pingpank; J P Hoffman; E A Ross; H S Cooper; N J Meropol; G Freedman; W H Pinover; T E LeVoyer; A R Sasson; B L Eisenberg Journal: J Gastrointest Surg Date: 2001 Mar-Apr Impact factor: 3.452
Authors: Karl Y Bilimoria; Mark S Talamonti; Stephen F Sener; Malcolm M Bilimoria; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem Journal: J Am Coll Surg Date: 2008-06-30 Impact factor: 6.113
Authors: V Moutardier; O Turrini; L Huiart; F Viret; M H Giovannini; V Magnin; B Lelong; E Bories; J Guiramand; A Sannini; M Giovannini; G Houvenaeghel; J L Blache; J C Moutardier; J R Delpero Journal: J Gastrointest Surg Date: 2004 May-Jun Impact factor: 3.452
Authors: William F Regine; Kathryn A Winter; Ross A Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Mahesh R Kudrimoti; Mitchel L Fromm; Michael G Haddock; Paul Schaefer; Christopher G Willett; Tyvin A Rich Journal: JAMA Date: 2008-03-05 Impact factor: 56.272
Authors: Erin E Burke; Schelomo Marmor; Pamela R Portschy; Beth A Virnig; Lawrence C Cho; Todd M Tuttle; Eric H Jensen Journal: HPB (Oxford) Date: 2015-02-28 Impact factor: 3.647
Authors: Christina L Roland; Matthew H G Katz; Ching-Wei D Tzeng; Heather Lin; Gauri R Varadhachary; Rachna Shroff; Milind Javle; David Fogelman; Robert A Wolff; Jean N Vauthey; Christopher H Crane; Jeffrey E Lee; Jason B Fleming Journal: Ann Surg Oncol Date: 2015-09-08 Impact factor: 5.344
Authors: Christina L Roland; Anthony D Yang; Matthew H G Katz; Deyali Chatterjee; Huamin Wang; Heather Lin; Jean N Vauthey; Peter W Pisters; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Jeffrey E Lee; Jason B Fleming Journal: Ann Surg Oncol Date: 2014-10-29 Impact factor: 5.344
Authors: William A Hall; Lauren E Colbert; Dana Nickleach; Jeffrey Switchenko; Yuan Liu; Theresa Gillespie; Joseph Lipscomb; Claire Hardy; David A Kooby; Roshan S Prabhu; John Kauh; Jerome C Landry Journal: J Gastrointest Oncol Date: 2014-04
Authors: Courtney J Pokrzywa; Daniel E Abbott; Kristina A Matkowskyj; Sean M Ronnekleiv-Kelly; Emily R Winslow; Sharon M Weber; Alexander V Fisher Journal: J Gastrointest Surg Date: 2019-01-31 Impact factor: 3.452
Authors: Stephanie H Greco; David A August; Mihir M Shah; Chunxia Chen; Dirk F Moore; Monika Masanam; Amber L Turner; Salma K Jabbour; Parisa Javidian; Miral S Grandhi; Timothy J Kennedy; H Richard Alexander; Darren R Carpizo; Russell C Langan Journal: Surg Open Sci Date: 2020-12-16